Table of Contents
Washington University Experience | NEOPLASMS (HEMATOLYMPHOID) | Lymphoma, immune-compromised | 9B Lymphoma (Case 9) CD20 2.jpg
Immunohistochemically stained sections show reactivity for the B-cell marker CD20 in the vast majority of tumor cells, and for B-cell marker CD79a within a smaller subset. Reactivity for T-cell marker CD3 (not shown) is identified only within rare, benign-appearing lymphocytes.
